Home > Healthcare > Biotechnology > Biotechnology R&D > Isothermal Nucleic Acid Amplification Technology (INAAT) Market

Isothermal Nucleic Acid Amplification Technology (INAAT) Market Share

Report ID: GMI5251
Published Date: Apr 2022
Report Format: PDF

Download Free Sample

Isothermal Nucleic Acid Amplification Technology Market Share

Some of the key market players operating in the isothermal nucleic acid amplification technology (INAAT) industry include

BD
Abbott (Alere)
BioMerieux SA
Eiken Chemical Co. Ltd
Hologic Inc. (Gen-Probe)
Lucigen
Meridian Bioscience, Inc.
OptiGene Limited
Qiagen NV
Quidel Corporation
Grifols
S.A.
Tecan Genomics Inc.
Thermo Fisher Scientific Inc.
Ustar Biotechnologies Ltd.

These industry participants are implementing various growth strategies with continued innovations and technology improvements to sustain in the isothermal nucleic acid amplification technology market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The isothermal nucleic acid amplification technology (INAAT) industry size had crossed USD 1.3 billion in 2021 and is poised to record an 11.8% CAGR between 2022 and 2028 owing to the expanding ageing population and rising technological developments.

The isothermal nucleic acid amplification technology (INAAT) market share from hospitals crossed USD 628 million in 2021 owing to the presence of fully automated instruments to offer quick test results in these facilities as compared to laboratories.

North America held over 43% of the isothermal nucleic acid amplification technology (INAAT) industry share in 2021 owing to the surging preference for these testing techniques over traditional diagnostic procedures in the region.

The INAAT market share from the blood screening application segment is poised to observe a 12% CAGR between 2022 and 2028 due to increasing adoption for understanding the overall blood health, metabolism, liver function, and mineral levels.